Krystal Biotech initiated at buy at Jefferies on Vyjuvek, gene delivery tech
Jefferies has initiated Krystal Biotech at buy citing growth in sales of Vyjuvek (beremagene geperpavec), a gene therapy for ...
Zacks Investment Research on MSN3d
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
Krystal Biotech KRYS announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...
Krystal Biotech initiated with a Buy at Jefferies
Jefferies analyst Roger Song initiated coverage of Krystal Biotech (KRYS) with a Buy rating and $245 price target Krystal is a commercial ...
Krystal Biotech Gets CHMP Backing for Vyjuvek Approval
Krystal Biotech said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Vyjuvek topical gene therapy for certain patients with the rare ...
PMLive3d
Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
Nasdaq6d
Krystal Biotech, Inc. Welcomes Positive EMA Recommendation for VYJUVEK® Approval in Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive recommendation for VYJUVEK® (beremagene geperpavec-svdt ...
Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...
Seeking Alpha6d
KRYS Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology ... The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Morningstar6d
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
These are not all the possible side effects with VYJUVEK. Call your healthcare provider for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Krystal Biotech ...
Nasdaq6d
Krystal Biotech Gets Positive CHMP Opinion For Vyjuvek To Treat Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. (KRYS) Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Vyjuvek ...
manilatimes6d
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
"The CHMP's recommendation for approval of VYJUVEK is an exciting step towards our goal of delivering the first ever corrective therapy to DEB patients across Europe,” said Suma Krishnan, President of ...